Renal Cell Carcinoma (RCC) Epidemiology Analysis and Forecast to 2033

1.1 Catalyst
1.2 Related reports
1.3 Upcoming reports

2.1 Disease background
2.2 Risk factors and comorbidities
2.3 Global and historical trends
2.4 8MM forecast methodology.
2.4.1 Sources
2.4.2 Forecast assumptions and methods.
2.4.3 Forecast assumption and methods: diagnosed incident cases of RCC
2.4.4 Forecast assumptions and methods: diagnosed incident cases of RCC by stage at diagnosis.
2.4.5 Forecast assumptions and methods: diagnosed incident cases of stage IV ccRCC by risk group.
2.4.6 Forecast assumptions and methods: diagnosed incident cases of stage IV nccRCC.
2.4.7 Forecast assumptions and methods: diagnosed incident cases of RCC by subtypes, papillary and chromophobe RCC.
2.4.8 Forecast assumptions and methods: diagnosed incident cases of RCC with VHL mutation by RCC subtype.
2.4.9 Forecast assumptions and methods: diagnosed incident cases RCC by BAP1 gene mutation.
2.4.10 Forecast assumptions and methods: diagnosed incident cases RCC by SETD2 gene mutation.
2.4.11 Forecast assumptions and methods: diagnosed incident cases RCC by ARID1A gene mutation.
2.5 Epidemiological forecast for RCC (2023-33)
2.5.1 Diagnosed incident cases of RCC.
2.5.2 Age-specific diagnosed incident cases of RCC
2.5.3 Sex-specific diagnosed incident cases of RCC
2.5.4 Diagnosed incident cases of RCC by stage at diagnosis.
2.5.5 Diagnosed incident cases of RCC by risk group.
2.5.6 Diagnosed incident cases of stage IV nccRCC.
2.5.7 Diagnosed incident cases of RCC by subtype - papillary and chromophobe RCC.
2.5.8 Diagnosed incident cases of RCC with VHL gene mutation by RCC subtype.
2.5.9 Diagnosed incident cases of RCC with genetic mutations BAP1, SETD2, and ARID1A
2.5.10 Five-year diagnosed prevalent cases of RCC
2.6 Discussion
2.6.1 Epidemiological forecast insight
2.6.2 COVID-19 impact.
2.6.3 Limitations of the analysis
2.6.4 Strengths of the analysis

3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Vice President of Disease Intelligence and Epidemiology
3.2.4 Global Head of Pharma Research, Analysis and Competitive Intelligence

• Contact the Publisher

Table 1: Summary of added data types
Table 2: Summary of updated data types
Table 3: Risk factors and comorbidities for RCC

Figure 1: 8MM, diagnosed incident cases of RCC, N, both sexes, ages =18 years, 2023 and 2033
Figure 2: 8MM, five-year diagnosed prevalent cases of RCC, N, both sexes, ages =18 years, 2023 and 2033
Figure 3: 8MM, diagnosed incidence of RCC, men and women, cases per 100,000 population, N, ages =18 years, 2013-33
Figure 4: 8MM, sources used to forecast the diagnosed incident cases of RCC
Figure 5: 8MM, sources used to forecast the diagnosed incident cases of RCC by stage at diagnosis
Figure 6: 8MM, sources used to forecast the diagnosed incident cases of stage IV nccRCC
Figure 7: 8MM, sources used and not used to forecast the diagnosed incident cases of stage IV ccRCC by risk group
Figure 8: 8MM, sources used and not used to forecast the diagnosed incident cases of RCC by subtypes papillary RCC and chromophobe RCC
Figure 9: 8MM, sources used and not used to forecast the diagnosed incident cases of RCC patients with VHL mutations
Figure 10: 8MM, sources used to forecast the diagnosed incident cases of RCC patients with a BAP1, SETD2, or ARID1A gene mutation
Figure 11: 8MM, diagnosed incident cases of RCC, N, both sexes, ages =18 years, 2023
Figure 12: 8MM, age-specific diagnosed incident cases of RCC by age, N, both sexes, 2023
Figure 13: 8MM, sex-specific diagnosed incident cases of RCC by sex, N, ages =18 years, 2023
Figure 14: 8MM, diagnosed incident cases of RCC by stage at diagnosis, N, both sexes, ages =18 years, 2023
Figure 15: 8MM, diagnosed incident cases of RCC by risk group, N, both sexes, ages =18 years, 2023
Figure 16: 8MM, diagnosed incident cases of stage IV nccRCC, N, both sexes, ages =18 years, 2023
Figure 17: 8MM, diagnosed incident cases of RCC by subtype - papillary and chromophobe RCC, N, both sexes, ages =18 years, 2023
Figure 18: 8MM, diagnosed incident cases of RCC with VHL gene mutation by RCC subtype, N, both sexes, ages =18 years, 2023
Figure 19: 8MM, diagnosed incident cases of RCC with genetic mutations BAP1, SETD2, and ARID1A, N, both sexes, ages =18 years, 2023
Figure 20: 8MM, five-year diagnosed prevalent cases of RCC, N, both sexes, ages =18 years, 2023